Figure 6.

AZD8055 regulates the 4E–BP1 mRNA pool by up-regulating ERK1/2 and p38 pathways. (a,b) HepG2 cells pretreated with (b) or without (a) 100 nM refametinib (Refa) or 10 μM SB203580 (SB) for 1 h were treated with 2 μM AZD8055 for indicated periods, and the relative mRNA expression of 4E–BP1 was determined by qPCR using specific primer. (c,d) Cells were treated with 2 μM AZD8055 for 2–24 h. Endogenous levels of eIF4E (c) and 4E–BP2 (d) mRNAs were measured by qPCR. The relative expression levels of target mRNAs were determined by comparing DMSO control with the experimental group after normalization using β–Actin mRNA. The data obtained from three independent experiments were presented as means ± S.D. Statistically significant differences were calculated using Student’s t-test and indicated as * p < 0.05 and *** p < 0.001.